TaiMed Biologics is pleased to announce our participation in BioEurope 2024, the largest biotech event in Europe, taking place from November 4–6, 2024, in Stockholm, Sweden. Visit us at booth #175 to learn about our expertise in developing therapeutics for HIV and the comprehensive CDMO services we provide.

Building on the success of Trogarzo®, the first and only monoclonal antibody approved for HIV treatment in the U.S., we are currently developing TMB-365/TMB-380, a long-acting dual monoclonal antibody combination therapy now in Phase 2a clinical study. This next-generation treatment aims to improve patient adherence and outcomes with extended dosing intervals.

In addition, we are excited to present our latest innovation—an antibody-drug conjugate (ADC) platform. This technology combines the precision of monoclonal antibodies with the potency of drug conjugates, marking the next frontier in HIV treatment.

We also welcome discussions on our Contract Development and Manufacturing Organization (CDMO) services, which offer tailored solutions from bench to market. We look forward to engaging with industry professionals and discussing how our capabilities can support your product development needs.

Join us at BioEurope 2024 to learn more about our offerings!
 
Back to the top